Misconceptions about calcimimetics

被引：23

作者：

Nemeth, E. F. ^{[1
]}

机构：

[1] NPS Pharmaceut Inc, Toronto, ON M5G 1L8, Canada

来源：

SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING | 2006年 / 1068卷

关键词：

calcimimetics; calcium receptor; allosteric modulators; drug discovery;

D O I：

10.1196/annals.1346.044

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Calcimimetics are ligands that activate the calcium receptor. Some are small molecules and of these, the most extensively studied are phenylalkylamines like cinacalcet. This compound is a positive allosteric modulator that selectively targets the parathyroid calcium receptor to inhibit the secretion of parathyroid hormone. Cinacalcet is the first calcimimetic compound to attain regulatory approval for the treatment of hyperparathyroidism resulting from end-stage renal disease. The discovery of calcimimetics and the receptor they act on are considered with the intent of extracting lessons relevant to medical research and the discovery of new drugs.

引用

页码：471 / 476

页数：6

共 22 条

[1] DRUGS FROM EMASCULATED HORMONES - THE PRINCIPLE OF SYNTOPIC ANTAGONISM [J].